Paper28291584
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Alley EW and 6 others. Lancet Oncol, 2017. Cited by 389 papers, by iCite.
Cite this record
ConductScience Library. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Papers, record 28291584. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28291584
- Disease
- non-small cell lung carcinoma1,066 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
- PubMed
- Publication types
- Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Antineoplastic Agents | Major topic |
| Mesothelioma | Major topic |
| Pleural Neoplasms | Major topic |
| Aged | |
| Arthralgia | |
| B7-H1 Antigen | |
| Fatigue | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Nausea | |
| Non-Randomized Controlled Trials as Topic | |
| Response Evaluation Criteria in Solid Tumors | |
| Retreatment |
Source PubMed
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02054806 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) | Results | Yes | ClinicalTrials.gov |
| NCT03447678 | Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. | Results | ClinicalTrials.gov | |
| NCT03918252 | Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 28495276 | Immune checkpoint inhibitors in malignant pleural mesothelioma. | https://conductscience.org/library/papers/28495276 |
Source PubMed
Cited by260
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 389 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42903807 | Reprogramming the tumor microenvironment in mesothelioma: from immune suppression to therapeutic opportunity. | Front Immunol | 2026 | https://conductscience.org/library/papers/42903807 | PubMed |
| 42806022 | VISTA drives tumour-intrinsic proliferation in mesothelioma cells. | Br J Cancer | 2026 | https://conductscience.org/library/papers/42806022 | PubMed |
| 42201625 | Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization. | Folia Microbiol (Praha) | 2026 | https://conductscience.org/library/papers/42201625 | PubMed |
| 42179971 | Nicotinamide mononucleotide enhances anti-tumor effect by resetting macrophages toward the inflammatory M1-like phenotype. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42179971 | PubMed |
| 41749932 | Clinical Importance of Molecular Biomarkers in Pleural Mesothelioma. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41749932 | PubMed |
| 41696561 | Immunotherapy advances in pleural mesothelioma. | Ther Adv Med Oncol | 2026 | https://conductscience.org/library/papers/41696561 | PubMed |
| 41553026 | Risk Factors of Hematological Toxicity of Mesothelioma Treatment-A Territory-Wide Retrospective Study. | Thorac Cancer | 2026 | https://conductscience.org/library/papers/41553026 | PubMed |
| 41510382 | Real-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China. | Transl Lung Cancer Res | 2025 | https://conductscience.org/library/papers/41510382 | PubMed |
| 41503777 | Association between immune-related adverse events and prognosis in immune checkpoint inhibitor therapy: A bibliometric and visual analysis. | Hum Vaccin Immunother | 2025 | https://conductscience.org/library/papers/41503777 | PubMed |
| 41463268 | Determinants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41463268 | PubMed |
| 41463246 | The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41463246 | PubMed |
| 41321671 | Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/41321671 | PubMed |
| 40904706 | Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40904706 | PubMed |
| 40874563 | Harnessing the Gut Microbiome in Cancer Immunotherapy: Mechanisms, Challenges, and Routes to Personalized Medicine-A Systematic Review. | Technol Cancer Res Treat | 2025 | https://conductscience.org/library/papers/40874563 | PubMed |
| 40775245 | Pleural mesothelioma. | Nat Rev Dis Primers | 2025 | https://conductscience.org/library/papers/40775245 | PubMed |
| 40506895 | Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/40506895 | PubMed |
| 40407381 | KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma. | Cancer Sci | 2025 | https://conductscience.org/library/papers/40407381 | PubMed |
| 40400943 | A bibliometric analysis of malignant pleural mesothelioma from 2010 to 2023. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/40400943 | PubMed |
| 40362535 | Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40362535 | PubMed |
| 40208070 | Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40208070 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| PEMBROLIZUMAB | CHEMBL3137343 | Results | 2 | https://conductscience.org/library/drugs/CHEMBL3137343 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28291584
GET https://conductscience.org/api/papers/v1/28291584/cited_by?page=2